Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9,515 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cabozantinib plus durvalumab in advanced gastroesophageal cancer and other gastrointestinal malignancies: Phase Ib CAMILLA trial results.
Saeed A, Park R, Dai J, Al-Rajabi R, Kasi A, Baranda J, Williamson S, Saeed A, Ripp J, Collins Z, Mulvaney K, Shugrue M, Firth-Braun J, Godwin AK, Madan R, Phadnis M, Sun W. Saeed A, et al. Among authors: dai j. Cell Rep Med. 2023 Feb 21;4(2):100916. doi: 10.1016/j.xcrm.2023.100916. Epub 2023 Jan 25. Cell Rep Med. 2023. PMID: 36702123 Free PMC article. Clinical Trial.
A phase II study of perioperative pembrolizumab plus mFOLFOX in patients with potentially resectable esophagus, gastroesophageal junction (GEJ), and stomach adenocarcinoma.
Sun W, Veeramachaneni N, Al-Rajabi R, Madan R, Kasi A, Al-Kasspooles M, Baranda J, Saeed A, Phadnis MA, Godwin AK, Olyaee M, Streeter N, Nagji A, Dai J, Williamson S. Sun W, et al. Among authors: dai j. Cancer Med. 2023 Aug;12(15):16098-16107. doi: 10.1002/cam4.6263. Epub 2023 Jun 16. Cancer Med. 2023. PMID: 37326317 Free PMC article. Clinical Trial.
Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort.
Saeed A, Park R, Pathak H, Al-Bzour AN, Dai J, Phadnis M, Al-Rajabi R, Kasi A, Baranda J, Sun W, Williamson S, Chiu YC, Osmanbeyoglu HU, Madan R, Abushukair H, Mulvaney K, Godwin AK, Saeed A. Saeed A, et al. Among authors: dai j. Nat Commun. 2024 Feb 20;15(1):1533. doi: 10.1038/s41467-024-45960-2. Nat Commun. 2024. PMID: 38378868 Free PMC article. Clinical Trial.
Transcriptomic Characterization of Endometrioid, Clear Cell, and High-Grade Serous Epithelial Ovarian Carcinoma.
Fridley BL, Dai J, Raghavan R, Li Q, Winham SJ, Hou X, Weroha SJ, Wang C, Kalli KR, Cunningham JM, Lawrenson K, Gayther SA, Goode EL. Fridley BL, et al. Among authors: dai j. Cancer Epidemiol Biomarkers Prev. 2018 Sep;27(9):1101-1109. doi: 10.1158/1055-9965.EPI-17-0728. Epub 2018 Jul 2. Cancer Epidemiol Biomarkers Prev. 2018. PMID: 29967001 Free PMC article.
Pupillary response: cognitive effort for breast cancer survivors.
Myers JS, Kahya M, Mitchell M, Dai J, He J, Moon S, Hamilton K, Valla M, O'Dea A, Klemp J, Kurylo M, Akinwuntan A, Devos H. Myers JS, et al. Among authors: dai j. Support Care Cancer. 2019 Mar;27(3):1121-1128. doi: 10.1007/s00520-018-4401-0. Epub 2018 Aug 10. Support Care Cancer. 2019. PMID: 30097791 Free PMC article.
9,515 results